Generic · Oral solution · Updated Nov 11, 2026
Codeine / promethazine 2 mg/mL / 1.25 mg/mL oral solution price what pharmacies pay, and what you should
Is my price fair?
Check the price you were quoted
Type what the pharmacy asked for codeine / promethazine 2 mg/ml / 1.25 mg/ml oral solution and see the markup over what they pay.
A benchmark from public data, not a price offer or medical advice. Prices vary by pharmacy, insurance and discount programs.
Codeine / promethazine 2 mg/mL / 1.25 mg/mL price history
What pharmacies pay for 473 mL, weekly- Now
- $34.58
- 52-week low
- $20.88
- 52-week high
- $34.58
- A year ago
- $19.78
Why the price changed
| Effective | Before | After | Change | Reason |
|---|---|---|---|---|
| Oct 21, 2026 | $0.0697 | $0.0731 | +4.9% | pharmacies' invoice prices changed (survey) |
| Sep 23, 2026 | $0.0682 | $0.0697 | +2.1% | pharmacies' invoice prices changed (survey) |
| Aug 19, 2026 | $0.0667 | $0.0682 | +2.3% | pharmacies' invoice prices changed (survey) |
| Jul 22, 2026 | $0.0643 | $0.0667 | +3.8% | pharmacies' invoice prices changed (survey) |
| Jun 17, 2026 | $0.0577 | $0.0643 | +11.4% | pharmacies' invoice prices changed (survey) |
| May 20, 2026 | $0.0506 | $0.0577 | +13.9% | pharmacies' invoice prices changed (survey) |
| Apr 22, 2026 | $0.0505 | $0.0506 | +0.4% | pharmacies' invoice prices changed (survey) |
| Mar 18, 2026 | $0.0501 | $0.0505 | +0.7% | pharmacies' invoice prices changed (survey) |
Prices per mL. Reasons are the ones the national survey gives: a survey rate change comes from pharmacies' own invoices; a published price change follows the maker's list price.
What people paid for codeine / promethazine 2 mg/ml / 1.25 mg/ml oral solution
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Every manufacturer and package code
5 companies sell codeine / promethazine 2 mg/ml / 1.25 mg/ml oral solution under 7 package codes (NDCs). Pharmacies pay the same per mL whichever maker they buy from - the national average is set for the generic as a group.
| Maker | Package codes | Per unit |
|---|---|---|
| Cosette Pharmaceuticals, Inc. | 0713-0823-75 | $0.0731 |
| Cranbury Pharmaceuticals, LLC | 27808-065-02 | $0.0731 |
| Quagen Pharmaceuticals LLC | 70752-139-06 70752-139-12 | $0.0731 |
| Atlantic Biologicals Corp. | 17856-0065-2 17856-0065-1 | - |
| Bryant Ranch Prepack | 72162-2042-2 | - |
All 7 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Questions to ask your pharmacist
- "What is your cash price, without insurance?" For low-cost generics it can be less than a copay.
- "Do you match other pharmacies or accept discount cards?" Many do, if you ask.
These are questions, not advice. Never change how you take a medicine without talking to your prescriber or pharmacist.
Official label & what changed
These highlights do not include all the information needed to use PROMETHAZINE HCL AND CODEINE PHOSPHATE ORAL SOLUTION safely and effectively. See full prescribing information for PROMETHAZINE HCL AND CODEINE PHOSPHATE ORAL SOLUTION.PROMETHAZINE HCL and CODEINE PHOSPHATE oral solution, CVInitial U.S. Approval: 1952
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME
Addiction, Abuse, and Misuse
Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Reserve Promethazine HCl and Codeine Phosphate Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. Assess each patient's risk prior to prescribing Promethazine HCl and Codeine Phosphate Oral Solution, prescribe Promethazine HCl and Codeine Phosphate Oral Solution for the shortest duration that is consistent with individual patient treatment goals, monitor all patients regularly for the development of addition or abuse, and refill only after reevaluation of the need for continued treatment. [see Warnings and Precautions (5.1)].
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of Promethazine HCl and Codeine Phosphate Oral Solution. Monitor for respiratory depression, especially during initiation of Promethazine HCl and Codeine Phosphate Oral Solution therapy or when used in patients at higher risk [see Warnings and Precautions (5.2)].
Accidental Ingestion
Accidental ingestion of even one dose of Promethazine HCl and Codeine Phosphate Oral Solution, especially by children, can result in a fatal overdose of codeine [see Warnings and Precautions (5.2)].
Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children
Life-threatening respiratory depression and death have occurred in children who received codeine. Most of the reported cases occurred following tonsillectomy and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism [see Warnings and Precautions (5.3)]. Promethazine HCl and Codeine Phosphate Oral Solution is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Contraindications (4)].
Avoid the use of Promethazine HCl and Codeine Phosphate Oral Solution in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine.
Promethazine and Respiratory Depression in Children
Postmarketing cases of respiratory depression, including fatalities have been reported with use of promethazine in pediatric patients. Children may be particularly sensitive to the additive respiratory depressant effects when promethazine is combined with other respiratory depressants, including codeine. [see Warnings and Precautions (5.4)].
Risk of Medication Errors
Ensure accuracy when prescribing, dispensing, and administering Promethazine HCl and Codeine Phosphate Oral Solution. Dosing errors can result in accidental overdose and death. Always use an accurate milliliter measuring device when measuring and administering Promethazine HCl and Codeine Phosphate Oral Solution [see Dosage and Administration (2.1), Warnings and Precautions (5.7)].
Interactions with Drugs Affecting Cytochrome P450 Isoenzymes
The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. Avoid the use of Promethazine HCl and Codeine Phosphate Oral Solution in patients who are taking a CYP3A4 inhibitor, CYP3A4 inducer, or 2D6 inhibitor [see Warnings and Precautions (5.9), Drug Interactions (7.1, 7.2, 7.3)].
Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of Promethazine HCl and Codeine Phosphate Oral Solution in patients taking benzodiazepines, other CNS depressants, or alcohol. [see Warnings and Precautions (5.10), Drug Interactions (7.4)]
Neonatal Opioid Withdrawal Syndrome
Promethazine HCl and Codeine Phosphate Oral Solution is not recommended for use in pregnant women [see Use in Specific Populations (8.1)]. Prolonged use of Promethazine HCl and Codeine Phosphate Oral Solution during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If Promethazine HCl and Codeine Phosphate Oral Solution is used for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Warnings and Precautions (5.20)].
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE- THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME
See full prescribing information for complete boxed warning.
Promethazine HCl and Codeine Phosphate Oral Solution exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor closely for these behaviors and conditions. (5.1)
Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or when used in patients at higher risk. (5.2)
Accidental ingestion of Promethazine HCl and Codeine Phosphate Oral Solution, especially by children, can result in a fatal overdose of codeine. (5.2)
Life-threatening respiratory depression and death have occurred in children who received codeine; most cases followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism. (5.3) Promethazine HCl and Codeine Phosphate Oral Solution is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. (4) Avoid the use of Promethazine HCl and Codeine Phosphate Oral Solution in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine.
Postmarketing cases of respiratory depression, including fatalities have been reported with use of promethazine in pediatric patients. Children may be particularly sensitive to the additive respiratory depressant effects when promethazine is combined with other respiratory depressants, including codeine. (5.4).
Ensure accuracy when prescribing, dispensing, and administering Promethazine HCl and Codeine Phosphate Oral Solution. Dosing errors can result in accidental overdose and death. (2.1, 5.7)
The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. Avoid the use of Promethazine HCl and Codeine Phosphate Oral Solution in patients who are taking a CYP3A4 inhibitor, CYP3A4 inducer, or 2D6 inhibitor. (5.9, 7.1, 7.2, 7.3)
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of Promethazine HCl and Codeine Phosphate Oral Solution in patients taking benzodiazepines, other CNS depressants, or alcohol. (5.10, 7.4)
Promethazine HCl and Codeine Phosphate Oral Solution is not recommended for use in pregnant women. Prolonged use of Promethazine HCl and Codeine Phosphate Oral Solution during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If Promethazine HCl and Codeine Phosphate Oral Solution is used for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. (5.19, 8.1)
Recent major changes (as listed on the label)
Boxed Warning 8/2017 and 6/2018
Indications and Usage (1) 6/2018
Dosage and Administration (2.1, 2.3) 6/2018
Dosage and Administration, Children under 12 years (2.2) Removed 8/2017
Dosage and Administration, Children under 18 years (2.2) Removed 6/2018
Contraindications (4) 8/2017 and 6/2018
Warnings and Precautions (5.3, 5.4) 8/2017
Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.9, 5.11, 5.16, 5.18, 5.19, 5.20) 6/2018
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about codeine / promethazine 2 mg/ml / 1.25 mg/ml oral solution
How much does codeine / promethazine 2 mg/ml / 1.25 mg/ml oral solution cost without insurance?
Pharmacies pay about $34.58 for 473 mL ($0.0731 per mL) as of November 11, 2026. A fair cash price is about $50.27: that cost plus a 15% margin and a $10.50 dispensing fee. Online cost-plus pharmacies charge around $49.77 including shipping.
Is my price for codeine / promethazine 2 mg/ml / 1.25 mg/ml oral solution fair?
Compare it with the fair cash price of $50.27 for 473 mL. Up to about $62.84 is fair; above $100.54 is high, and worth asking the pharmacy for its cash price or trying another pharmacy. Check your quote.
Is codeine / promethazine 2 mg/ml / 1.25 mg/ml oral solution getting more expensive?
Over the last four weeks the price pharmacies pay rose 4.9%. Over a year it rose 74.8%. See the 52-week chart.
Who makes codeine / promethazine 2 mg/ml / 1.25 mg/ml oral solution?
5 companies: Cosette Pharmaceuticals, Inc., Cranbury Pharmaceuticals, LLC, Quagen Pharmaceuticals LLC, Atlantic Biologicals Corp., Bryant Ranch Prepack. See every package code.
Is codeine / promethazine in shortage?
No shortage is reported right now. We check every day.
Has codeine / promethazine been recalled?
No recalls are on record.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about codeine / promethazine 2 mg/ml / 1.25 mg/ml oral solution
No comments yet. Questions, tips, what worked for you - start the conversation.